🔗 Visit the ClinicalTrials.gov page for NCT01139775
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Targeting DNA damage response in cancer therapy. | Cancer Sci | 2014 | 1.16 |
| 2 | Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. | Front Oncol | 2014 | 1.06 |
| 3 | Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. | Invest New Drugs | 2014 | 0.92 |
| 4 | Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. | Clin Cancer Res | 2015 | 0.90 |